# Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration

> **NCT05891548** · PHASE2 · COMPLETED · sponsor: **Clearside Biomedical, Inc.** · enrollment: 60 (actual)

## Conditions studied

- Neovascular Age-related Macular Degeneration

## Interventions

- **DRUG:** CLS-AX
- **DRUG:** Aflibercept

## Key facts

- **NCT ID:** NCT05891548
- **Lead sponsor:** Clearside Biomedical, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-31
- **Primary completion:** 2024-08-20
- **Final completion:** 2024-08-20
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2025-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05891548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05891548, "Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05891548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*